Upperton Announces Strategic Investment into Futorque X-Tablet Press

September 17, 2019

The device can produce up to 130,000 tablets per hour and completes design of experiment and research studies with little material and multiple tooling formats.

Upperton Pharma Solutions, a Nottingham, UK-based oral and inhalation drug product development company, has made a strategic investment into the Futorque X- tablet press by KG-Pharma, the company announced in a Sept. 17, 2019 press release. The new device supports R&D studies and production batches.

Capable of producing up to 130,000 tablets per hour, the tablet press completes design of experiment and research studies with little material and is capable of accommodating multiple tooling formats. The device is also the first equipment investment made by the company as a follow-up to receiving MHRA approval for its GMP clinical manufacturing facility.

“This is an extremely exciting time for the business as we continue to expand on our GMP processing capabilities,” said Paul Kelsall, director of clinical manufacture, in the press release. “We are always looking to increase our capabilities in our people, plant, and processing equipment, and this is a huge step forward as we look to support our clients clinical manufacturing requirements.”

“The investment in this high specification, versatile instrumented tablet machine provides Upperton [s]cientists with the equipment to manufacture clinical supplies and will also allow them to generate the data required to gain in-depth understanding and knowledge of process and formulation behavior during compression that is key to supporting our clients during future scale-up, production, and registration stages of their product development,” added Dr. Ian Lafferty, technical consultant, in the press release. 

Source: Upperton Pharma Solutions